Results 61 to 70 of about 857,892 (246)
Annals of the Rheumatic Diseases, 2021 Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
V. Furer +28 more
semanticscholar +1 more source
FEBS Open Bio, EarlyView.Cleavable N‐terminal Thioredoxin fusion enabled soluble expression and purification of otherwise insoluble SARS‐CoV‐2 Nucleocapsid (N) protein. A four‐step purification strategy yielded highly homogeneous, RNA‐free N protein. Binding assays showed high RNA affinity (Kd ~ 28 nm). The study will facilitate high‐resolution structural studies of N protein,
Shweta Singh, Gagan D. Gupta
wiley +1 more source
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Science, 2021 Vaccine protects against B1.1.7 variant The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene.
A. Muik +11 more
semanticscholar +1 more source
Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024
FEBS Open Bio, EarlyView.The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior +5 more
wiley +1 more source
COVID-19 vaccine development: milestones, lessons and prospects
Signal Transduction and Targeted Therapy, 2022 With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit,
Maochen Li +9 more
semanticscholar +1 more source
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
New England Journal of Medicine, 2021 Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in children younger than 12 years of age. Methods A phase 1, dose-finding study and an ongoing phase 2–3 randomized trial are being conducted to ...
E. Walter +33 more
semanticscholar +1 more source
, 2019 Since the introduction of smallpox vaccination more than two centuries ago, vaccines have been—and still are—instrumental in the prevention of infectious diseases. Nowadays vaccines form a heterogeneous group of pharmaceutical products that differ in several aspects from other biopharmaceuticals.
Jiskoot, Wim +3 more
openaire +2 more sources
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin +10 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Managing long COVID in people with multiple sclerosis and related disorders (pwMSRD) is complex due to overlapping symptoms. To address evidence gaps, we evaluated long COVID susceptibility in pwMSRD versus controls and its associations with multi‐domain function and disability.
Chen Hu +15 more
wiley +1 more source